Collectively, our studies have yielded amongthe most potent and effective strategies for pharmacological RIG-Iactivation described to date and have identified LNPs as a previouslyunexplored and translationally advanced nanotechnology platform forharnessing the potential of RIG-I in cancer immunotherapy. Here, RIGI is linked to cancer.